Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 16,836 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Thrombocytopenia
Interventions: flow cytometry, DNA methylation analysis, cytogenetic analysis, decitabine, microarray analysis, gene expression analysis, pharmacological study, polymorphism analysis; Other · Drug · Genetic
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions: Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 21,379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 250
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more

Conditions: HIV Infection
Interventions: TMC114; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more

Conditions: Respiratory Distress Syndrome, Adult, Acute Lung Injury
Interventions: Sivelestat; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more

Conditions: Kaposi's Sarcoma
Interventions: VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more

Conditions: Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
Interventions: Cognivue; Device
Lead sponsor: Cognivue, Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Irvine, California • Visalia, California • Boca Raton, Florida + 1 more

Conditions: HIV Infections
Interventions: Couples HIV testing and counseling, Individual HIV testing and counseling; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 17 Years to 65 Years · Male only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus
Interventions: Usual care plus peer-mentors, Usual care plus incentives, Usual Care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: TDF/FTC; Drug
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hereditary Angioedema
Interventions: CSL312; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Spiramycin; Drug
Lead sponsor: Rhone-Poulenc Rorer; Industry
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more

Conditions: Leigh Syndrome
Interventions: EPI-743; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 4
States / cities: Stanford University, California • Akron, Ohio • Houston, Texas + 1 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sleep, Metabolic Syndrome
Interventions: Self- management for adequate sleep intervention (SASI); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Sepsis, Septic Shock
Interventions: vasopressin - early initiation, vasopressin - standard initiation; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Interventions: Cognitive-Behavioral Therapy, Wait-list; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 11 Years to 14 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • St. Petersburg, Florida

Conditions: Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Premenstrual Tension, Menstrual Related Mood Disorder
Interventions: EnBrace HR Softgel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 52 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovary Syndrome, Insulin Resistance
Interventions: Cinnamon Supplementation, Placebo (wheat flour); Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sepsis, AKI, Neurotoxicity
Interventions: anti-pseudomonal cephalosporin, anti-pseudomonal penicillin; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2,634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Antisynthetase Syndrome
Interventions: Descartes-08, Placebo; Drug · Other
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Orange, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more

Conditions: Hiv, Chlamydia, Gonorrhea
Interventions: all2GETHER; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years to 34 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients

Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection

CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Extending Sleep to Reverse Metabolic Syndrome in Middle-aged Adults: Acceptability and Feasibility of a Sleep Intervention

Prospective Study of Lymphoproliferative Diseases

Early Versus Late Adjunctive Vasopressin in Septic Shock

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents

EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

Descartes-08 in Autoantibody Myositis

Effectiveness of Relationship Education for Reducing HIV Incidence Among Men Who Have Sex With Men